EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma

EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma

<p dir="ltr">PARP1 inhibitors (PARPi) are currently used in the clinic for the treatment of ovarian and breast cancers, yet their therapeutic efficacy against hepatocellular carcinoma (HCC) has been disappointing. To ensure therapeutic efficacy of PARPi against HCC, a disease often d...

Full description

Saved in:
Bibliographic Details
Main Author: Qiongzhu Dong (5156150) (author)
Other Authors: Yi Du (634812) (author), Hui Li (32376) (author), Chunxiao Liu (436462) (author), Yongkun Wei (9694532) (author), Mei-Kuang Chen (14917347) (author), Xixi Zhao (4251673) (author), Yu-Yi Chu (636524) (author), Yufan Qiu (8734875) (author), Lunxiu Qin (624841) (author), Hirohito Yamaguchi (14884460) (author), Mien-Chie Hung (102628) (author)
Published: 2019
Subjects:
Biomedical and clinical sciences
Oncology and carcinogenesis
PARP1 inhibitors (PARPi)
Hepatocellular carcinoma (HCC)
Therapeutic efficacy
Biomarkers
PARPi resistance
EGFR
MET
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items